Sponsor: Ascendis Pharma Inc.
Sponsor Study ID: ASND0038
Study Title: A Randomized, Phase 2, Open-label Study of TransCon IL-2 B/y Monotherapy, TransCon IL-2 B/y in Combination with TransCon TLR7/8 Agonist, TransCon TLR7/8 Agonist in Combination with Pembrolizumab, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
CTO #: 103868
NCT Number: NCT05980598
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lip, Oral Cavity and Pharynx
Study Objectives: To evaluate MPR of TransCon TLR7/8 Agonist in Combination with Pembrolizumab and TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ as Compared with Pembrolizumab Monotherapy